Bod Science has announced substantial upgrades to its Aqua Phase Delivery Technology

Bod Science Limited (ASX: BOD) provided an update on the development of the Aqua Phase delivery technology. Bod is doing two PK tests to show that CBD in Aqua Phase technology has a higher bioavailability than in MCT oil. The first PK study uses micro-sampling techniques to examine the drug's bioavailability in capillary blood.

This information is crucial for managing disorders in the body since it shows how much the drug may reach the extremities and organs. Ten volunteers are now participating in this study, which has already started. The bioavailability in venous blood is the subject of the second PK research. Bellbery has granted ethics permission for this Phase I PK Study and recruitment for the 12 study participants who will be chosen has already begun.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com